Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD) (FAAH-I MULTI)

Conditions

Addictive Behaviors | Mental Health & Behavioral Research

Phase IIB

Volunteers
Health Professionals

What is the purpose of this trial?

Brief Summary:

A Phase 2B, 8-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults with DSM-5 Current Cannabis Use Disorder (CUD)

Ages
18 years - 60 years
Gender
Both

Find out more about who can participate in this trial

Trial with
National Institute on Drug Abuse (NIDA)
Start Date
01/14/2019
End Date
12/31/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Deepak Cyril Dsouza, MBBS, MD
Professor of Psychiatry; Director Schizophrenia Neuropharmacology Research Group at Yale (SNRGY); Director, Neurobiological Studies Unit, VACHS; Director, VA-CMHC Schizophrenia Research Clinic

Sub-Investigators

Last Updated
07/15/2021
Study HIC
#2000022450